TUDCA MAX

Each bottle contains: 60 capsules
Servings per container: 30

Each capsule contains:
Tauroursodeoxycholic Acid (TUDCA): 250mg
Ox Bile Extract (45% Cholic Acid): 50mg 

Other ingredients: Gelatin (bovine), NuFlow (rice hull). 

• Liver support & detox*
• Improved bile flow*
• Improved fat digestion*
• Increased fat-soluble vitamin absorption*
• Supports gut health*
• Aids in toxin elimination via bile*
• Neuroprotective *
• May assist in dissolving gallstones*
• May improve liver and muscle insulin sensitivity*
• May reduce elevated liver enzyme markers*
• May lower cholesterol*
• May reduce cholestasis *
• May improve conditions of liver cirrhosis, fatty liver, and hepatitis*
  
  

*These statements have not been evaluated by the Food and Drug Association or Health Canada. These products are not meant to diagnose, treat, cure, or prevent any diseases.

Generally, the serving size should be taken on a relatively empty stomach. For some, this can be an hour or two after a meal. Some people may also fare better with taking it well before eating, for example first thing in the morning, 30+ minutes prior to breakfast. It can be split into 2 separate doses throughout the day if desired.

The reasoning for this is because bile salts are highly alkaline, and are excreted into the intestine after our food has been acidified by stomach acid. The combination between the acidified food, and the alkaline bile salts are what create the digestion of food, fats, and absorption of vitamins (think of adding baking soda to vinegar). We want to wait to give the food enough time to be acidified, before adding in the alkaline bile salts. However, each person is different, and therefore we recommend each person find their optimal dosing and timing methods.

1. Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci. 1996 Apr;41(4):809-15. doi: 10.1007/BF02213140. PMID: 8674405.

2.  Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein S. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010 Aug;59(8):1899-905. doi: 10.2337/db10-0308. Epub 2010 Jun 3. PMID: 20522594; PMCID: PMC2911053.

3. da-Silva WS, Ribich S, Arrojo e Drigo R, Castillo M, Patti ME, Bianco AC. The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure. FEBS Lett. 2011 Feb 4;585(3):539-44. doi: 10.1016/j.febslet.2010.12.044. Epub 2011 Jan 14. PMID: 21237159; PMCID: PMC3133948.

4. Kusaczuk M. Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives. Cells. 2019 Nov 20;8(12):1471. doi: 10.3390/cells8121471. PMID: 31757001; PMCID: PMC6952947.

5. Vang S, Longley K, Steer CJ, Low WC. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med. 2014 May;3(3):58-69. doi: 10.7453/gahmj.2014.017. PMID: 24891994; PMCID: PMC4030606.

6. Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications. Handb Exp Pharmacol. 2019;256:237-264. doi: 10.1007/164_2019_241. PMID: 31236688.

7. Song M, Zhang F, Fu Y, Yi X, Feng S, Liu Z, Deng D, Yang Q, Yu M, Zhu C, Zhu X, Wang L, Gao P, Shu G, Ma X, Jiang Q, Wang S. Tauroursodeoxycholic acid (TUDCA) improves intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets. J Anim Sci Biotechnol. 2022 Jun 8;13(1):73. doi: 10.1186/s40104-022-00713-3. PMID: 35672805; PMCID: PMC9175448.

8. Tronstad RR, Berland S, Tjora E, El Jellas K, Aukrust I, Kristensen K, Tveitnes D, Molven A, Marschall HU, Rao A, Dawson PA. Fat Malabsorption and Ursodeoxycholic Acid Treatment in Children With Reduced Organic Solute Transporter-α (SLC51A) Expression. JPGN Rep. 2022 Aug;3(3):e229. doi: 10.1097/pg9.0000000000000229. Epub 2022 Jul 25. PMID: 36148443; PMCID: PMC9491403.

9. Zangerolamo L, Vettorazzi JF, Rosa LRO, Carneiro EM, Barbosa HCL. The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sci. 2021 May 1;272:119252. doi: 10.1016/j.lfs.2021.119252. Epub 2021 Feb 23. PMID: 33636170.

10. Boatright JH, Nickerson JM, Moring AG, Pardue MT. Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor. 2009 Sep;2(3):149-159. doi: 10.1007/s12177-009-9030-x. Epub 2009 Aug 27. PMID: 20046852; PMCID: PMC2798994.
11. Arai Y, Choi B, Kim BJ, Rim W, Park S, Park H, Ahn J, Lee SH. Tauroursodeoxycholic acid (TUDCA) counters osteoarthritis by regulating intracellular cholesterol levels and membrane fluidity of degenerated chondrocytes. Biomater Sci. 2019 Aug 1;7(8):3178-3189. doi: 10.1039/c9bm00426b. Epub 2019 May 30. PMID: 31143889.
12. Wang H, Guo Y, Han W, Liang M, Xiao X, Jiang X, Yu W. Tauroursodeoxycholic Acid Improves Nonalcoholic Fatty Liver Disease by Regulating Gut Microbiota and Bile Acid Metabolism. J Agric Food Chem. 2024 Sep 11;72(36):20194-20210. doi: 10.1021/acs.jafc.4c04630. Epub 2024 Aug 28. PMID: 39193771.
13. The effect of Tauroursodeoxycholic acid (TUDCA) and gut microbiota on murine gallbladder stone formation